Targeted therapies against Dll4 may be particularly interesting from a tumour vasculature perspective [148], as blockade of Dll4 causes hypersprouting in the vasculature by altering the tip/stalk cell balance, which leads to a poorer blood supply for the tumours. This evidence concerns the gene DLL4 and neoplasm.